Residual gastric contents

1. GLP-1 receptor agonists are linked with higher residual gastric contents in humans (patients undergoing EGD alone or with concurrent colonoscopy, adjusted for covariates) (aOR 13.31 (95% CI 5.07-34.93); unadjusted OR 15.20 (95% CI 5.98-38.61)).

   “GLP-1 RAs users had higher odds of increased RGC in both unadjusted [OR 15.20 (95% CI 5.98-38.61)] and adjusted analyses [aOR = 13.31 (95% CI 5.07-34.93)].”

   Humanspatients undergoing EGD alone or with concurrent colonoscopy, adjusted for covariatesstomachn = 3,746

   Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) on Increased Residual Gastric Content in Patients With and Without Concurrent Colonoscopy: A Retrospective Case-Control Study

   Journal of clinical medicine·Mar 10, 2026

2. GLP-1 receptor agonists increase residual gastric contents in humans (despite adherence to standard preoperative fasting protocols).

   “Observational evidence demonstrated an association between GLP-1 RA use, particularly semaglutide, and increased residual gastric contents or delayed gastric emptying despite adherence to standard fasting protocols.”

   Reviewdespite adherence to standard preoperative fasting protocolsstomach

   Perioperative Safety Considerations and Surgical Outcomes Associated With GLP-1-Based Therapies: A Systematic Review

   Cureus·Sep 25, 2026

More on GLP-1 receptor agonists

1. Diabetes-related complications are linked with higher residual gastric contents in humans (aOR = 8.89 (3.15-25.12)).

   “Other significant risk factors for RGC included diabetes-related complications [aOR = 8.89 (3.15-25.12)].”

   Humansstomachn = 3,746

   Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) on Increased Residual Gastric Content in Patients With and Without Concurrent Colonoscopy: A Retrospective Case-Control Study

   Journal of clinical medicine·Mar 10, 2026

More on Diabetes-related complications